RECRUITING

Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects

Conditions

Bioequivalence Study in Healthy Subjects PK/PD torsemide Spironolactone bioequivalence diuresis extended release immediate release

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study examines the bioavailability and bioequivalence of single dose of a Fixed Dose Combination (FDC) tablet (12 mg Extended-Release Torsemide and 15mg Spironolactone). The goal of this study is to determine PK/PD effects of the FDC, 10 mg Torsemide alone, 25mg Aldactone® (Spironolactone) alone, and 10 mg Torsemide and 25 mg Aldactone® (Spironolactone) taken together in healthy subjects.

Official Title

Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Subjects

Quick Facts

Study Start:2025-06

Study Completion:2026-06

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07015671

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
1. Healthy human adult subjects within the age range of 18 to 45 years \[both inclusive\]. 2. Weight not less than 50 kg for male and 45 kg for female and BMI 18.50 to 29.99 kg/m2 \[both inclusive\]. 3. Willingness to provide written informed consent to participate in the study. 4. Subjects should be non-smoker \[defined as someone who has stopped smoking for a year before the date of screening\] and should not be consuming tobacco containing products. 5. Free of significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, 12-lead ECG, Chest X-ray \[PA view\]. 6. Absence of disease markers of HIV 1 and 2, Hepatitis B and C and Syphilis. 7. Subject should be literate. 8. Male subjects must be using two acceptable methods of contraception (e.g., spermicidal gel plus condom) for the entire duration of the study, and upto the study completion visit. Subjects must refrain from fathering a child in the next two weeks following the last study drug administration or have undergone vasectomy (vasectomy must have been done more than 6 months prior to first dosing). Contraceptive usage requirement will be conveyed during the inform consent process. Subjects will be advised to follow effective method of contraception until 2 weeks after the last dose is given. 9. Female subjects of childbearing potential must be using two acceptable methods of contraception, (e.g., intra-uterine device (IUD) plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the study and for two weeks following the last study drug administration. Contraceptive usage requirement will be conveyed during the inform consent process (or) Postmenopausal women for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy have been performed).	1. History or presence of significant: cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, musculoskeletal, psychiatric disease/disorder. 2. History or presence of significance: 3. Hypersensitivity or allergy to Torsemide, Spironolactone or any of the excipients. 4. History of alcohol or drug abuse in the past one year. 5. Family history of bleeding disorders. 6. History of difficulty in passing urine or emptying the bladder or of incontinence. 7. Have donated 500 mL or more blood within 90 days before receiving the first dose of the study drug. 8. Subjects who have participated in another clinical study in the past 3 months prior to commencement of this study. 9. Any difficulty in the accessibility of forearm veins for cannulation or blood sampling and or difficulty with donating blood. 10. Refuse to abstain from food for at least 10 h prior to dosing and for at least 4 h after dosing in each period. 11. Refuse to abstain from fluid for at least 1 h before and 1 h after dosing in each period (except 240 ± 2 mL water given for dosing). 12. Found positive during breath alcohol test done during period one check-in and inability to abstain from alcohol till the end of the study. 13. Found positive during urine drug screening done prior to period one check-in. 14. Found positive screening results for Hepatitis B, Hepatitis C, HIV, or Syphilis. 15. History of difficulty in swallowing tablets. 16. Received any medication \[including over-the-counter products\], herbal products for 14days preceding the study. 17. Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication. 18. History of dehydration from diarrhea, vomiting, or any other reason within 24 hours prior to check-in of period one. 19. Consumption of xanthine-containing food and beverages (chocolates, tea, coffee, or cola drinks) for at least 48 hours prior to check-in of period one. 20. Consumption of grapefruit or its products within the 48 hours prior to check-in of period one. 21. Female subjects are found to be positive during pregnancy tests done prior to period one check-in. 22. Lactating females. 23. Investigator/Physician feels that it is not in the subject's and/or study's best interest to enroll the subject.

Inclusion Criteria

Exclusion Criteria

1. Healthy human adult subjects within the age range of 18 to 45 years \[both inclusive\].
2. Weight not less than 50 kg for male and 45 kg for female and BMI 18.50 to 29.99 kg/m2 \[both inclusive\].
3. Willingness to provide written informed consent to participate in the study.
4. Subjects should be non-smoker \[defined as someone who has stopped smoking for a year before the date of screening\] and should not be consuming tobacco containing products.
5. Free of significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, 12-lead ECG, Chest X-ray \[PA view\].
6. Absence of disease markers of HIV 1 and 2, Hepatitis B and C and Syphilis.
7. Subject should be literate.
8. Male subjects must be using two acceptable methods of contraception (e.g., spermicidal gel plus condom) for the entire duration of the study, and upto the study completion visit. Subjects must refrain from fathering a child in the next two weeks following the last study drug administration or have undergone vasectomy (vasectomy must have been done more than 6 months prior to first dosing). Contraceptive usage requirement will be conveyed during the inform consent process. Subjects will be advised to follow effective method of contraception until 2 weeks after the last dose is given.
9. Female subjects of childbearing potential must be using two acceptable methods of contraception, (e.g., intra-uterine device (IUD) plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the study and for two weeks following the last study drug administration. Contraceptive usage requirement will be conveyed during the inform consent process (or) Postmenopausal women for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy have been performed).

1. History or presence of significant: cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, musculoskeletal, psychiatric disease/disorder.
2. History or presence of significance:
3. Hypersensitivity or allergy to Torsemide, Spironolactone or any of the excipients.
4. History of alcohol or drug abuse in the past one year.
5. Family history of bleeding disorders.
6. History of difficulty in passing urine or emptying the bladder or of incontinence.
7. Have donated 500 mL or more blood within 90 days before receiving the first dose of the study drug.
8. Subjects who have participated in another clinical study in the past 3 months prior to commencement of this study.
9. Any difficulty in the accessibility of forearm veins for cannulation or blood sampling and or difficulty with donating blood.
10. Refuse to abstain from food for at least 10 h prior to dosing and for at least 4 h after dosing in each period.
11. Refuse to abstain from fluid for at least 1 h before and 1 h after dosing in each period (except 240 ± 2 mL water given for dosing).
12. Found positive during breath alcohol test done during period one check-in and inability to abstain from alcohol till the end of the study.
13. Found positive during urine drug screening done prior to period one check-in.
14. Found positive screening results for Hepatitis B, Hepatitis C, HIV, or Syphilis.
15. History of difficulty in swallowing tablets.
16. Received any medication \[including over-the-counter products\], herbal products for 14days preceding the study.
17. Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
18. History of dehydration from diarrhea, vomiting, or any other reason within 24 hours prior to check-in of period one.
19. Consumption of xanthine-containing food and beverages (chocolates, tea, coffee, or cola drinks) for at least 48 hours prior to check-in of period one.
20. Consumption of grapefruit or its products within the 48 hours prior to check-in of period one.
21. Female subjects are found to be positive during pregnancy tests done prior to period one check-in.
22. Lactating females.
23. Investigator/Physician feels that it is not in the subject's and/or study's best interest to enroll the subject.

Contacts and Locations

Study Contact

Salim Shah, PhD, JD

CONTACT

703-627-1934

salim.shah@sarfez.com

Principal Investigator

Salim Shah, PhD, JD

STUDY_CHAIR

Sarfez Pharmaceuticals, Inc.

Study Locations (Sites)

Sarfez Pharmaceuticals

Vienna, Virginia, 22182

United States

Collaborators and Investigators

Sponsor: Sarfez Pharmaceuticals, Inc.

Salim Shah, PhD, JD, STUDY_CHAIR, Sarfez Pharmaceuticals, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06

Study Completion Date2026-06

Study Record Updates

Study Start Date2025-06

Study Completion Date2026-06

Terms related to this study

Keywords Provided by Researchers

torsemide
Spironolactone
bioequivalence
diuresis
extended release
immediate release
PK/PD

Additional Relevant MeSH Terms

Bioequivalence Study in Healthy Subjects
PK/PD